secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001213900-23-066904
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences reports record Q2 net revenue of $10.8M; posts $3.3M income from operations
--------------------------------------------------------------------------------

- Q2 net revenue $10.8M (up 151% YoY); six-month net revenue $17.5M (up 133% YoY).
- Q2 income from operations $3.3M vs loss of $1.4M in Q2 2022; six-month income $2.2M vs loss of $4.5M.
- Net loss narrowed to $1.5M ($0.03/sh) from $8.9M ($0.18/sh) in Q2 2022; six-month loss $5.0M ($0.10) vs $10.4M ($0.21).
- Sales growth driven by $4.1M increase in MENA region in Q2; U.S. sales also recovering.
- Cash and equivalents $1.4M at June 30, 2023, down from $2.0M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390023066904/0001213900-23-066904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390023066904/ea183077-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-066904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer